Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DHR 
Danaher Corporation (DHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: DHR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $244.35
1 Year Target Price $244.35
| 19 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.92% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 139.74B USD | Price to earnings Ratio 41.52 | 1Y Target Price 244.35 |
Price to earnings Ratio 41.52 | 1Y Target Price 244.35 | ||
Volume (30-day avg) 26 | Beta 0.78 | 52 Weeks Range 170.73 - 278.43 | Updated Date 09/12/2025 |
52 Weeks Range 170.73 - 278.43 | Updated Date 09/12/2025 | ||
Dividends yield (FY) 0.61% | Basic EPS (TTM) 4.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.21% | Operating Margin (TTM) 20.12% |
Management Effectiveness
Return on Assets (TTM) 4.01% | Return on Equity (TTM) 6.68% |
Valuation
Trailing PE 41.52 | Forward PE 22.78 | Enterprise Value 154142628304 | Price to Sales(TTM) 5.82 |
Enterprise Value 154142628304 | Price to Sales(TTM) 5.82 | ||
Enterprise Value to Revenue 6.42 | Enterprise Value to EBITDA 22.82 | Shares Outstanding 716051968 | Shares Floating 637128384 |
Shares Outstanding 716051968 | Shares Floating 637128384 | ||
Percent Insiders 11.05 | Percent Institutions 82.81 |
Upturn AI SWOT
Danaher Corporation
Company Overview
History and Background
Danaher Corporation was founded in 1969 as DMG, Inc., a real estate investment trust. It evolved through acquisitions and strategic shifts, transforming into a diversified science and technology conglomerate. Key milestones include its focus on environmental and applied solutions, life sciences, and diagnostics.
Core Business Areas
- Life Sciences: Provides tools and technologies for life science research, including genomics, proteomics, and cell biology. Focuses on enabling researchers to accelerate discovery and improve patient outcomes.
- Diagnostics: Offers diagnostic instruments, reagents, and consumables used in hospitals, reference laboratories, and point-of-care settings. Focuses on improving diagnostic accuracy and efficiency.
- Environmental & Applied Solutions: Provides solutions for water quality, product identification, and packaging. Focuses on ensuring water safety, traceability, and brand protection.
Leadership and Structure
Danaher is led by Rainer M. Blair as President and CEO. The organizational structure is decentralized, with operating companies managed independently under the Danaher Business System (DBS).
Top Products and Market Share
Key Offerings
- Cytiva Bioprocessing: Provides bioprocessing technologies and solutions for the development and manufacturing of biopharmaceuticals, including cell culture, filtration, and chromatography. Competitors: Sartorius, Merck KGaA. Estimated Revenue from Cytiva is approximately $8 Billion.
- Beckman Coulter Diagnostics: Offers diagnostic systems and assays for clinical laboratories, covering areas such as hematology, chemistry, and immunoassay. Competitors: Roche, Siemens Healthineers, Abbott. Estimated revenue $4 Billion
- Hach Water Quality: Provides water quality analysis instruments and reagents for municipal, industrial, and environmental applications. Competitors: Xylem, Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The life sciences, diagnostics, and environmental & applied solutions industries are experiencing growth driven by factors such as increasing healthcare spending, aging populations, and stricter environmental regulations.
Positioning
Danaher is a leading player in its target markets, with a strong focus on innovation, operational excellence (through DBS), and strategic acquisitions. Its competitive advantage lies in its diversified portfolio, strong brands, and continuous improvement culture.
Total Addressable Market (TAM)
The combined TAM for Danaher's segments is estimated to be several hundred billion dollars. Danaher is positioned to capture a significant portion of this TAM through organic growth, acquisitions, and expansion into new markets.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified business portfolio
- Proven acquisition strategy
- Danaher Business System (DBS)
- Strong cash flow generation
Weaknesses
- High debt levels (due to acquisitions)
- Exposure to cyclical markets
- Integration risks associated with acquisitions
- Potential for product obsolescence
Opportunities
- Expanding into emerging markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increasing demand for diagnostics and life sciences products
- Growing focus on sustainability and water quality
Threats
- Economic downturns
- Increased competition
- Changes in healthcare regulations
- Technological disruptions
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Siemens Healthineers (SEMHF)
- Roche Holding AG (RHHBY)
- Agilent Technologies (A)
- Merck KGaA (MKKGY)
Competitive Landscape
Danaher competes based on product innovation, quality, service, and brand reputation. It benefits from its diversified portfolio and DBS, but faces competition from larger and more specialized players.
Major Acquisitions
Abcam
- Year: 2023
- Acquisition Price (USD millions): 5700
- Strategic Rationale: Expands Danaher's life sciences portfolio with a leading provider of biological reagents and tools.
Aldevron
- Year: 2021
- Acquisition Price (USD millions): 9600
- Strategic Rationale: Strengthens Danaher's bioprocessing capabilities with a leading provider of plasmid DNA, mRNA, and recombinant proteins.
Growth Trajectory and Initiatives
Historical Growth: Danaher has historically grown through a combination of organic growth and acquisitions. Its growth rate has varied depending on economic conditions and acquisition activity.
Future Projections: Analyst estimates for future growth vary. Refer to financial websites and research reports for consensus estimates.
Recent Initiatives: Recent initiatives include acquisitions in life sciences and diagnostics, investments in research and development, and expansion into new geographies.
Summary
Danaher is a strong, diversified science and technology company with a proven track record of growth through acquisitions and operational excellence. Its decentralized structure and DBS drive continuous improvement and innovation. High debt levels and cyclical market exposure are potential concerns, but overall, Danaher is well-positioned for future growth within its target markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Danaher Corporation Investor Relations
- Financial News Articles
- Analyst Reports
- Company SEC Filings (10-K, 10-Q)
- Yahoo Finance
- Bloomberg
- Seeking Alpha
- Corporate Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. Financial data is subject to change. This analysis uses public available data and is deemed to be reliable, but accuracy cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Danaher Corporation
Exchange NYSE | Headquaters Washington, DC, United States | ||
IPO Launch date 1979-01-05 | President, CEO & Director Mr. Rainer M. Blair | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 61000 | Website https://www.danaher.com |
Full time employees 61000 | Website https://www.danaher.com | ||
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.